Novartis has announced positive top-line results from its Phase III trials – NEPTUNUS-1 and NEPTUNUS-2 – evaluating ianalumab (VAY736) in adults with active Sjögren’s
At a time when artificial intelligence (AI) is promising to revolutionise medical practice and transform patient outcomes, the Australian Medical Association is calling for
Alcon has announced that it will acquire STAAR Surgical Company, manufacturer of the Implantable Collamer Lens (ICL).
A Phase IIb clinical trial is set to begin for EXN407 – a novel eye-drop therapy for non-proliferative diabetic retinopathy and diabetic macular oedema
DISCLAIMER : THIS WEBSITE IS INTENDED FOR USE BY HEALTHCARE PROFESSIONALS ONLY.
By agreeing & continuing, you are declaring that you are a registered Healthcare professional with an appropriate registration. In order to view some areas of this website you will need to register and login.
If you are not a Healthcare professional do not continue.
